Synthetic Cannabinoids Gaining Popularity in States Without Legalized Medical or Recreational Cannabis

In states where medical or recreational cannabis is not yet legalized, hemp-derived synthetic cannabinoids are emerging as an alternative option. According to BrightField, a US-based analytics company, sales of synthetic cannabinoid products are expected to exceed $300 billion by 2022. This trend has been driven largely by the growing demand for CBD and other non-psychoactive cannabinoids from consumers looking for natural health remedies. The popularity of synthetic cannabinoids is also being driven by the fact that they can be produced in large quantities and at a much lower cost than natural cannabinoids derived from hemp plants. Furthermore, they can be formulated into various products such as edibles, tinctures, topicals, and capsules with ease. Despite their increasing popularity, there are still some concerns about the safety of these products due to their lack of regulation and oversight. For instance, many synthetic cannabinoid products contain higher levels of THC than what is found in natural cannabis plants which could lead to adverse effects on users’ health if consumed in high doses. Additionally, there have been reports of some synthetic cannabinoid products containing dangerous contaminants such as heavy metals or pesticides which could pose serious health risks if ingested. In order to ensure consumer safety and prevent potential abuse of these products, it is important that regulatory bodies take steps to regulate them more closely. This includes establishing clear guidelines for production processes and testing protocols as well as setting limits on the amount of THC allowed in each product. It is also essential that manufacturers provide accurate labeling information so consumers know exactly what they are purchasing when buying these products online or in stores.